

Michelangelo Fiorentino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3232995/publications.pdf>

Version: 2024-02-01

122
papers

2,645
citations

201385

27
h-index

233125

45
g-index

124
all docs

124
docs citations

124
times ranked

4999
citing authors

#	ARTICLE	IF	CITATIONS
1	Antitissue transglutaminase antibodiesâ€™™ normalization after starting a gluten-free diet in a large population of celiac children-a real-life experience. <i>Digestive and Liver Disease</i> , 2022, 54, 336-342.	0.4	6
2	Microbiota and prostate cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 1058-1065.	4.3	23
3	HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan) <i>Tj ETQq1 1 0.784314 rgBIqOverlo</i>	1.0	11
4	The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103561.	2.0	16
5	The impact of multiparametric MRI features to identify the presence of prevalent cribriform pattern in the peripheral zone tumors. <i>Radiologia Medica</i> , 2022, 127, 174-182.	4.7	3
6	Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade. <i>Clinical Epidemiology</i> , 2022, Volume 14, 59-70.	1.5	2
7	PI-RADS version 2.1 for the evaluation of transition zone lesions: a practical guide for radiologists. <i>British Journal of Radiology</i> , 2022, 95, 20210916.	1.0	11
8	The EORTC protocol for sentinel lymph node biopsy (SLNB) reveals a high number of nodal nevi and a strong association with nevus-associated melanoma. <i>Pathology Research and Practice</i> , 2022, , 153805.	1.0	1
9	Intraâ€™epithelial nonâ€™canonical Activin A signaling safeguards prostate progenitor quiescence. <i>EMBO Reports</i> , 2022, 23, e54049.	2.0	8
10	The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 113.	3.5	9
11	Hematoxylin and eosin or double stain for CD34/SOX10: Which is better for the detection of lymphovascular invasion in cutaneous melanoma?. <i>Pathology Research and Practice</i> , 2022, 233, 153876.	1.0	2
12	Low level of interobserver concordance in assessing histological subtype and tumor grade in patients with penile cancer may impair patient care. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 879-886.	1.4	6
13	The role of MRI in the detection of local recurrence: Added value of multiparametric approach and Signal Intensity/Time Curve analysis. <i>Archivio Italiano Di Urologia Andrologia</i> , 2022, 94, 25-31.	0.4	1
14	Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples. <i>Pathology Research and Practice</i> , 2022, 233, 153893.	1.0	3
15	Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions?. <i>Pathology Research and Practice</i> , 2022, 234, 153937.	1.0	1
16	BRAF and MLH1 Analysis Algorithm for the Evaluation of Lynch Syndrome Risk in Colorectal Carcinoma Patients: Evidence-Based Data from the Analysis of 100 Consecutive Cases. <i>Journal of Molecular Pathology</i> , 2022, 3, 115-124.	0.5	1
17	Real-time Augmented Reality Three-dimensional Guided Robotic Radical Prostatectomy: Preliminary Experience and Evaluation of the Impact on Surgical Planning. <i>European Urology Focus</i> , 2021, 7, 1260-1267.	1.6	38
18	The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 433.e1-433.e7.	0.8	10

#	ARTICLE	IF	CITATIONS
19	Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. <i>Molecular Cancer Research</i> , 2021, 19, 475-484.	1.5	22
20	The Leydig cell tumour Scaled Score (LeSS): a method to distinguish benign from malignant cases, with additional correlation with <i>MDM2</i> and <i>CDK4</i> amplification. <i>Histopathology</i> , 2021, 78, 290-299.	1.6	21
21	Histological and immunohistochemical characterization of 17 gonadal tumours in koi carp (<i>Cyprinus carpio koi</i>). <i>Journal of Fish Diseases</i> , 2021, 44, 273-285.	0.9	4
22	Pathological post-mortem findings in lungs infected with SARS-CoV-2. <i>Journal of Pathology</i> , 2021, 253, 31-40.	2.1	61
23	Diagnosis and Molecular Profiling of Lung Cancer by Percutaneous Ultrasound-Guided Biopsy of Superficial Metastatic Sites Is Safe and Highly Effective. <i>Respiration</i> , 2021, 100, 515-522.	1.2	6
24	Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study. <i>Diagnostics</i> , 2021, 11, 184.	1.3	0
25	Interchangeability of light and virtual microscopy for histopathological evaluation of prostate cancer. <i>Scientific Reports</i> , 2021, 11, 3257.	1.6	11
26	Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing. <i>Pathology Research and Practice</i> , 2021, 219, 153350.	1.0	3
27	A narrative review of individualized treatments of genitourinary tumors: is the future brighter with molecular evaluations?. <i>Translational Andrology and Urology</i> , 2021, 10, 1553-1561.	0.6	5
28	Case Report: The Complete Remission of a Mixed Germ Cell Tumor With Somatic Type Malignancy of Sarcoma Type With a GCT-Oriented Therapy: Clinical Findings and Genomic Profiling. <i>Frontiers in Oncology</i> , 2021, 11, 633543.	1.3	2
29	The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis. <i>Cancers</i> , 2021, 13, 1575.	1.7	4
30	Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience. <i>Pathology Research and Practice</i> , 2021, 220, 153410.	1.0	1
31	The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6237.	1.8	15
32	Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. <i>Pathology Research and Practice</i> , 2021, 222, 153440.	1.0	10
33	[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 390-409.	3.3	7
34	Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	5
35	A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34. <i>Pathology Research and Practice</i> , 2021, 227, 153637.	1.0	5
36	PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, 423-431.	1.1	34

#	ARTICLE	IF	CITATIONS
37	Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. <i>Anti-Cancer Drugs</i> , 2021, 32, 74-81.	0.7	4
38	Liquid biopsies in urological cancers: what we need to know before starting using them. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 135-139.	1.5	5
39	PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 213-220.	0.6	28
40	Pd-ligand 1 is expressed in inflammatory cells but not in neoplastic cells in hepatocellular carcinoma: An immunohistochemical study. <i>Acta Histochemica</i> , 2020, 122, 151468.	0.9	1
41	Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience. <i>Lung Cancer</i> , 2020, 149, 5-9.	0.9	22
42	Pulmonary adenocarcinoma with psammoma bodies is associated with a specific endobronchial ultrasound pattern and a high prevalence of actionable driver mutations. <i>Lung Cancer</i> , 2020, 147, 204-208.	0.9	2
43	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 755-763.	1.1	14
44	Atezolizumab in a Cohort of pretreated, advanced, non-small cell lung cancer patients with rare Histological Subtypes (CHANCE trial). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091598.	1.4	5
45	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , 2020, 9, 2051.	1.8	65
46	Dual TMRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers. <i>Diagnostics</i> , 2020, 10, 1109.	1.3	3
47	Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma. <i>European Urology Open Science</i> , 2020, 20, 62-71.	0.2	20
48	Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095480.	1.4	9
49	Interobserver agreement between pathologist, pulmonologist and molecular pathologist to estimate the tumour burden in rapid on-site evaluation smears from endosonography and guided bronchoscopy. <i>Cytopathology</i> , 2020, 31, 303-309.	0.4	6
50	Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. <i>Carcinogenesis</i> , 2020, 41, 904-908.	1.3	1
51	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020, 12, 1449.	1.7	72
52	Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 666.	1.7	24
53	Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer. <i>Pathology Research and Practice</i> , 2020, 216, 153012.	1.0	4
54	Next-generation sequencing revealing TP53 mutation as potential genetic driver in dermal deep-seated melanoma arising in giant congenital nevus in adult patients: A unique case report and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 1164-1169.	0.7	5

#	ARTICLE	IF	CITATIONS
55	Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. <i>Pathology</i> , 2020, 52, 297-309.	0.3	35
56	Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional Clear Cell Renal Cell Carcinoma: A Comparative Phenotypical and Mutational Analysis. <i>Diagnostics</i> , 2020, 10, 123.	1.3	5
57	Frequency of somatic mutations in head and neck melanoma: A single institution experience. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 515-517.	1.5	6
58	BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients. <i>American Journal of Clinical Pathology</i> , 2020, 153, 664-671.	0.4	18
59	Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study. <i>Clinical Lung Cancer</i> , 2020, 21, e464-e473.	1.1	24
60	Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms. <i>Current Drug Targets</i> , 2020, 21, 1286-1292.	1.0	10
61	PD1/PD-L1 Axis in Uro-oncology. <i>Current Drug Targets</i> , 2020, 21, 1293-1300.	1.0	6
62	Patterns of positive surgical margins after open radical prostatectomy and their association with clinical recurrence. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 464-473.	3.9	13
63	Which patients with clinical localized renal mass would achieve the trifecta after partial nephrectomy? The impact of surgical technique. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 339-349.	3.9	36
64	Pathological features and outcomes of incidental renal cell carcinoma in candidate solid organ donors. <i>Kidney Research and Clinical Practice</i> , 2020, 39, 487-494.	0.9	0
65	Clinical significance of ROS1 5'UTR deletions in non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 135, 88-91.	0.9	10
66	BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4807-4812.	1.0	4
67	Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer. <i>Clinical Respiratory Journal</i> , 2019, 13, 590-597.	0.6	4
68	BRAF V600E Status and Stimulated Thyroglobulin at Ablation Time Increase Prognostic Value of American Thyroid Association Classification Systems for Persistent Disease in Differentiated Thyroid Carcinoma. <i>International Journal of Endocrinology</i> , 2019, 2019, 1-7.	0.6	0
69	Gain of FGF4 is a frequent event in KIT/PDGFR α /SDH/RAS WT GIST. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 636-642.	1.5	22
70	The Metabolic Landscape of Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 28-36.	2.6	68
71	A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 2047-2054.	1.1	11
72	PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes. <i>European Urology Oncology</i> , 2019, 2, 214-221.	2.6	34

#	ARTICLE	IF	CITATIONS
73	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988554.	1.4	25
74	Estrogen Receptors and Melanoma: A Review. <i>Cells</i> , 2019, 8, 1463.	1.8	41
75	A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. <i>European Urology</i> , 2019, 76, 33-40.	0.9	26
76	MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report. <i>Translational Oncology</i> , 2019, 12, 116-121.	1.7	37
77	Vitamin A Deficiency Due to Selective Eating as a Cause of Blindness in a High-Income Setting. <i>Pediatrics</i> , 2018, 141, S439-S444.	1.0	22
78	Immune checkpoint inhibitors for metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , 2018, 64, 11-20.	3.4	76
79	MRI Displays the Prostatic Cancer Anatomy and Improves the Bundles Management Before Robot-Assisted Radical Prostatectomy. <i>Journal of Endourology</i> , 2018, 32, 315-321.	1.1	68
80	Fading With Time of PD-L1 Immunoreactivity in Non-“Small Cells Lung Cancer Tissues: A Methodological Study. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 489-494.	0.6	38
81	FOXP3 ⁺ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer. <i>Prostate</i> , 2018, 78, 40-47.	1.2	41
82	Role of microRNAs in the main molecular pathways of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2018, 24, 2647-2660.	1.4	66
83	Emerging Molecular Technologies in Genitourinary Tumors. <i>Frontiers in Oncology</i> , 2018, 8, 489.	1.3	1
84	Persistent Mullerian duct syndrome: Report of two cases with phenotypical immunohistochemical profiling. <i>Urologia</i> , 2018, 85, 177-181.	0.3	1
85	Unusual metastatic localization to the kidney of basaloid squamous cell carcinoma of the oropharynx. <i>Urologia</i> , 2018, 85, 182-185.	0.3	0
86	Genomic profiles of primary and metastatic esophageal adenocarcinoma identified via digital sorting of pure cell populations: results from a case report. <i>BMC Cancer</i> , 2018, 18, 889.	1.1	3
87	Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer. <i>Lung Cancer</i> , 2018, 126, 9-14.	0.9	29
88	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. <i>International Journal of Molecular Sciences</i> , 2018, 19, 732.	1.8	29
89	Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors. <i>Prostate</i> , 2018, 78, 1172-1180.	1.2	17
90	Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 305-312.e1.	0.9	19

#	ARTICLE	IF	CITATIONS
91	Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas. <i>Oncotarget</i> , 2018, 9, 17895-17905.	0.8	6
92	Circulating Antioxidant Levels and Risk of Prostate Cancer by <i>TMPRSS2:ERG</i> . <i>Prostate</i> , 2017, 77, 647-653.	1.2	11
93	Unusual asymptomatic presentation of bladder cancer metastatic to the penis. <i>Pathology Research and Practice</i> , 2017, 213, 717-720.	1.0	6
94	Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 711-715.	1.4	12
95	ROC-king onwards: intraepithelial lymphocyte counts, distribution & role in coeliac disease mucosal interpretation. <i>Gut</i> , 2017, 66, 2080-2086.	6.1	57
96	Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. <i>Nature Communications</i> , 2017, 8, 420.	5.8	91
97	Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody. <i>Molecular and Clinical Oncology</i> , 2017, 7, 113-120.	0.4	16
98	Molecular Imaging and Precision Medicine in Prostate Cancer. <i>PET Clinics</i> , 2017, 12, 83-92.	1.5	9
99	Oestrogen and progesterone receptors in melanoma and nevi: an immunohistochemical study. <i>European Journal of Dermatology</i> , 2017, 27, 254-259.	0.3	9
100	Wide spectrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. <i>Oncotarget</i> , 2017, 8, 7328-7335.	0.8	19
101	Real-time elastography for the detection of fibrotic and inflammatory tissue in patients with stricturing Crohn's disease. <i>Journal of Ultrasound</i> , 2017, 20, 273-284.	0.7	26
102	Immune checkpoint inhibitors and prostate cancer: a new frontier?. <i>Oncology Reviews</i> , 2016, 10, 293.	0.8	47
103	Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. <i>Cancer Causes and Control</i> , 2016, 27, 1043-1047.	0.8	5
104	Renal oncocytosis: a clinicopathological and cytogenetic study of 42 tumours occurring in 11 patients. <i>Pathology</i> , 2016, 48, 41-46.	0.3	14
105	Complete pathological response after chemo-radiation in anaplastic thyroid cancer: A report of two cases. <i>Acta Oncologica</i> , 2016, 55, 530-532.	0.8	3
106	MET DNA Alterations in NSCLC Letter. <i>Clinical Cancer Research</i> , 2016, 22, 3697-3698.	3.2	1
107	Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. <i>Carcinogenesis</i> , 2016, 37, 262-268.	1.3	7
108	Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review. <i>Endocrine Pathology</i> , 2016, 27, 55-64.	5.2	52

#	ARTICLE	IF	CITATIONS
109	Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. <i>British Journal of Cancer</i> , 2016, 114, 939-944.	2.9	19
110	Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 765-772.	3.2	25
111	MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma—a step towards personalized therapy. <i>Clinical Epigenetics</i> , 2015, 7, 129.	1.8	22
112	The Prognostic Impact of Tumor Size on Cancer-Specific and Overall Survival Among Patients With Pathologic T3a Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e235-e241.	0.9	26
113	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. <i>Genetics in Medicine</i> , 2015, 17, 391-395.	1.1	41
114	Nodal Occult Metastases in Intermediate- and High-Risk Prostate Cancer Patients Detected Using Serial Section, Immunohistochemistry, and Real-Time Reverse Transcriptase Polymerase Chain Reaction: Prospective Evaluation With Matched-Pair Analysis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e55-e64.	0.9	14
115	Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFR genotype evaluated by next generation sequencing (NGS). <i>Oncotarget</i> , 2015, 6, 42243-42257.	0.8	20
116	Revised Gleason Grading System Is a Better Predictor of Indolent Prostate Cancer at the Time of Diagnosis: Retrospective Clinical-Pathological Study on Matched Biopsy and Radical Prostatectomy Specimens. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 325-329.	0.9	4
117	Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFR wild-type GIST. <i>European Journal of Human Genetics</i> , 2014, 22, 32-39.	1.4	90
118	Revisiting the role of pathological analysis in transarterial chemoembolization-treated hepatocellular carcinoma after transplantation. <i>World Journal of Gastroenterology</i> , 2014, 20, 13538.	1.4	4
119	Fatty Acid Synthase Polymorphisms, Tumor Expression, Body Mass Index, Prostate Cancer Risk, and Survival. <i>Journal of Clinical Oncology</i> , 2010, 28, 3958-3964.	0.8	113
120	Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 519-532.	3.0	328
121	Nanotechnology-Related Environment, Health, and Safety Research. <i>Environmental Health Perspectives</i> , 2009, 117, .	2.8	3
122	Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. <i>Hepatology</i> , 1995, 21, 1543-1546.	3.6	35